Skip to main content

Perioperative intravenous lidocaine for the prevention of chronic postsurgical pain: a systematic review and meta-analysis of randomized controlled trials

Journal
Frontiers in medicine (Q1)
Published
28 September 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Wei-Jing Zhu, Ran An, Qian-Yun Pang, Xiao-Long Liang
PMID
42865434
DOI
10.3389/fmed.2026.1927770

Why clinicians should know about it

Abstract

BACKGROUND: Chronic postsurgical pain (CPSP) poses a significant clinical burden, yet the efficacy of perioperative intravenous lidocaine for its prevention remains inconclusive. This meta-analysis evaluates its preventive efficacy and administration regimens. METHODS: PubMed, EMBASE, and the Cochrane Library were searched from database inception to a prespecified cutoff of June 1, 2025; final electronic searches were run on June 8, 2025, to identify randomized controlled trials (RCTs) comparing perioperative intravenous lidocaine with placebo/standard care in adults. Primary outcomes were CPSP incidence at 3 and 6 months postoperatively. RESULTS: Eighteen RCTs (1,391 patients) were included. Intravenous lidocaine significantly reduced CPSP incidence (RR = 0.67; 95% CI: 0.53 to 0.85; P = 0.001) and neuropathic pain risk (RR = 0.60; 95% CI: 0.43 to 0.85; P = 0.004) at 3 months. However, the reduction in the incidence of CPSP was not statistically significant at 6 months (RR = 0.68; 95% CI: 0.41 to 1.12; P = 0.13). Exploratory subgroup analyses of CPSP incidence at 3 months showed favorable pooled estimates in selected surgery and administration-regimen categories; however, they did not demonstrate a statistically significant difference between regimen categories. Safety assessment was limited by inconsistent adverse-event reporting and limited pharmacokinetic monitoring. CONCLUSION: Perioperative intravenous lidocaine reduces CPSP at 3 months, but evidence of an effect on CPSP incidence at 6 months remains inconclusive. Future trials should incorporate structured pharmacokinetic monitoring and exposure-response analyses and evaluate lidocaine's additive value alongside optimal regional anesthesia. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251063756, identifier CRD420251063756.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.